0A4D Stock Overview
A clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Equillium, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.54 |
52 Week High | US$3.12 |
52 Week Low | US$0.49 |
Beta | 1.76 |
1 Month Change | -12.99% |
3 Month Change | -31.56% |
1 Year Change | 156.92% |
3 Year Change | -75.56% |
5 Year Change | n/a |
Change since IPO | -72.33% |
Recent News & Updates
Recent updates
Shareholder Returns
0A4D | GB Biotechs | GB Market | |
---|---|---|---|
7D | -10.9% | 1.3% | 1.0% |
1Y | 156.9% | -19.3% | 6.7% |
Return vs Industry: 0A4D exceeded the UK Biotechs industry which returned -19.3% over the past year.
Return vs Market: 0A4D exceeded the UK Market which returned 6.8% over the past year.
Price Volatility
0A4D volatility | |
---|---|
0A4D Average Weekly Movement | 22.5% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A4D's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0A4D's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 44 | Bruce Steel | www.equilliumbio.com |
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.
Equillium, Inc. Fundamentals Summary
0A4D fundamental statistics | |
---|---|
Market cap | US$54.29m |
Earnings (TTM) | -US$12.13m |
Revenue (TTM) | US$37.89m |
1.4x
P/S Ratio-4.5x
P/E RatioIs 0A4D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0A4D income statement (TTM) | |
---|---|
Revenue | US$37.89m |
Cost of Revenue | US$0 |
Gross Profit | US$37.89m |
Other Expenses | US$50.02m |
Earnings | -US$12.13m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.34 |
Gross Margin | 100.00% |
Net Profit Margin | -32.01% |
Debt/Equity Ratio | 0% |
How did 0A4D perform over the long term?
See historical performance and comparison